N/A N=31 Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: MATRICS Consensus Cognitive Battery (MCCB) Composite Score — 32.30; 33.87; 32.50; 35.47 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=334 Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS
HIV-1 Infection
Primary: Cumulative Rate of Progression-Free Survival by Week 48 for ET+ART vs. PTX+ART — 19.7; 49.8 Cumulative events per 100 persons
Phase 1 N=280 Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers
Inhalational Anthrax
Primary: Number of Participants Who Experienced Adverse Events — 88; 27 Participants
N/A N=82 TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions
Peripheral Arterial Disease
Primary: Number of Participants Free From Target Lesion Revascularization (TLR) — 52 Participants
Phase 3 N=374 A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine
Pain
Primary: Time Weighted Sum of Pain Relief Rating (PRR) and Pain Intensity Difference (PID) Scores From 0 to 8 Hours Post-dose (SPRID 0-8): Ibuprofen + Caffeine Versus Ibuprofen…
Phase 3 N=994 Effects of Abatacept in Patients With Early Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants in Simple Disease Activity Index (SDAI) Remission at Week 24 — 21.3; 16.0 Percentage of participants — p=0.2359
Phase 1 N=40 Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers
Inhalational Anthrax
Primary: Number of Participants Who Experienced Adverse Events — 14; 13 Participants
Phase 2 N=254 Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Opioid-Induced Constipation
Primary: Change From Baseline in 8-Week SBM Frequency Rate (SBMs/Week) — 1.474; 2.799; 3.382 Number of SBMs per week — p=0.0035
Phase 3 N=182 Efficacy and Safety Clinical Trial of Tenoten for Children Liquid Dosage Form Therapy in Infants With Sequelae of Perinatal Brain Injury
Sequelae of Perinatal Brain Injury
Primary: Percentage of Patients With a 4 and More Point Increase of the Total Score According to Jurba-Mastyukova Psychomotor Development Scale by the End of the Treatment…
Phase 3 N=745 Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Tear Production — 16.6; 9.2 Percentage of eyes
N/A N=606 Smoking Cessation in Rural Hospitals
Smoking Cessation
Primary: Number of Participants With 7-day Point Prevalence Abstinence From Cigarettes, Validated — 57; 48 Participants — p=0.46
Phase 1 N=14 Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects
Schizophrenia
Primary: Lurasidone Cmax — 50.2 ng/mL
Phase 2 N=40 Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) of Carfilzomib and Pegylated Liposomal Doxorubicin (Phase I - Part 1). — 56; 30 mg/m^2
Phase 2 N=175 A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine
Influenza
Primary: CD4+ and CD8+ Th1 Cellular Immunogenicity on Day 42 — 0.5; 5.9; 1.0; 0.2 fold change — p=0.45
Phase 3 N=180 Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin
Neck Pain · Back Pain · Spasm
Primary: Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Day 3 of Treatment — 20.0; 28.9; 60.0; 46.7 percentage of participants — p=0.6179